Thierry André
蒂埃里·安德烈
MD, PhD
Professor of Medical Oncology; Head, Department of Medical Oncology肿瘤内科学教授；肿瘤内科主任
👥Biography 个人简介
Thierry André is a leading French medical oncologist whose work fundamentally shaped the adjuvant treatment of colon cancer and, more recently, the immunotherapy of MSI-H colorectal cancer. He was the principal investigator of the MOSAIC trial, establishing FOLFOX4 as standard adjuvant therapy for stage III colon cancer, and subsequently led the KEYNOTE-177 European effort and the NICHE and NIVOLUMAB/IPILIMUMAB trials in MSI-H disease. His research bridges early-stage adjuvant chemotherapy optimization and advanced immunotherapy, reflecting a career-long commitment to improving outcomes across all stages of colorectal cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
MOSAIC Trial — FOLFOX4 Adjuvant Standard
Principal investigator of the pivotal MOSAIC phase III trial demonstrating that FOLFOX4 (oxaliplatin plus infusional fluorouracil/leucovorin) significantly improved disease-free and overall survival versus LV5FU2 in stage II/III colon cancer, establishing FOLFOX as the international adjuvant standard.
MSI-H Immunotherapy in Early and Advanced CRC
Led European investigator efforts on KEYNOTE-177 and subsequent trials evaluating nivolumab plus ipilimumab in MSI-H/dMMR metastatic CRC, contributing pivotal data supporting immune checkpoint blockade across disease stages.
Lynch Syndrome Surveillance and Chemoprevention
Conducted prospective studies characterizing oncological outcomes and surveillance strategies in Lynch syndrome patients, providing evidence for tailored screening intervals and the potential role of aspirin chemoprevention.
Representative Works 代表性著作
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC trial): long-term results
Journal of Clinical Oncology (2009)
Six-year follow-up of the MOSAIC trial confirming sustained overall survival benefit of FOLFOX4 in stage III colon cancer, cementing its role as the global adjuvant standard.
Nivolumab plus ipilimumab in previously treated patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: CheckMate 142 final results
Journal of Clinical Oncology (2021)
Final analysis of the CheckMate 142 trial demonstrating durable clinical benefit and manageable safety with nivolumab plus ipilimumab in pretreated MSI-H/dMMR mCRC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 蒂埃里·安德烈 的研究动态
Follow Thierry André's research updates
留下邮箱，当我们发布与 Thierry André（Hôpital Saint-Antoine, Sorbonne University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment